BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$85.25 USD
+0.28 (0.33%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $85.27 +0.02 (0.02%) 6:32 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Brokerage Reports
BioMarin Pharmaceutical Inc. [BMRN]
Reports for Purchase
Showing records 801 - 816 ( 816 total )
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage with a Neutral Rating and 12-Month Price Target of $26
Provider: DAWSON JAMES SECURITIES, INC.
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company Acquires Early Stage Drug Candidate for Pompe Disease.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials Missed And 2010 Guidance Was Lowered. Pipeline Progress: So Far So Good For PEG-PAL.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Consensus And Comparables: We Believe Q2 Consensus Is Achievable.Is Trading In-Line With Comparables But Getting More Expensive; Fair Value Moves to $26.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials Beat By A Penny On The Bottom Line But Product Sales Were Mixed. At First Glance GALNS Data Looks Mixed But May Be Good Enough. Fair Value to $24.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Consensus And Comparables: We Believe Q1 Consensus Is Somewhat High But Achievable. BMRN Is Trading In-Line With Comparables But Getting More Expensive.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet
Provider: Merriman Curhan Ford & Co.
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Positive Preliminary Data on GALNS for MPS IVA; Acquisition of LEAD Therapeutics; 2010 Guidance Issued.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Consensus And Comparables: We Believe Q4 Consensus Is Achievable And BMRN Is Trading In-Line With Comparables; Fair Value Moves to $23.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Life Sciences - Biotechnology - Biotech Balance Sheet
Provider: MERRIMAN CURHAN FORD & CO.